Some plans preferentially cover one over the other based on which manufacturer offered better rebates that year
STEP: Semaglutide Treatment Effect in People with obesity
The secretions tend to be more fluid than that of the goblet cells, but the degree varies with the stimulus
Pipeline report flags continued pressure The insurer's annual outlook, aimed at private plan sponsors, lists GLP-1 therapies among the leading themes of 2026 and warns that ongoing launches of newer, more expensive drugs are putting increased financial pressure on private drug plans [Source: ab.bluecross.ca/plans/group/drug-pipeline-2026.php]
2022 Nov;21(22):2365-2378
For many, the combined effect of flat pricing, tax-advantaged accounts, and zero insurance processing yields the lowest true cost of therapy available